Apollomics
APLM----
Apollomics (APLM)
Apollomics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of oncology therapies to harness the immune system and ta...
- Open
- --
- High
- --
- Low
- --
- Prev. Close
- --
- Volume
- --
- Turnover
- --
- Avg Price
- --
- Bid/Ask Ratio
- --
- Amplitude
- --
- 52wk High
- --
- Volume Ratio
- --
- Turnover Ratio
- --
Apollomics Analyst Rating
View MoreForecast & Rating
Jun 6, 2024Price forecast
$200.00998.30%
Forecast & RatingBuy
1analysts
- Strong buy0.00%
- Buy100.00%
- Hold0.00%
- Sell0.00%
- Strong sell0.00%
News
- PUBT · Jul 21 at 02:13 PM
Apollomics appoints Hung-Hsien Yen to board after two directors resign
- Global Report · Jul 18 at 04:12 AM
Strategic Spinoffs and Bold Overhauls Across 10 Under-the-Radar Stocks
- benzinga_article · Jul 17 at 12:05 PM
12 Health Care Stocks Moving In Friday's Intraday Session
- rttnews · Jul 16 at 09:58 PM
Top Biotech Gainers: CDNA Soars On Medicare Policy, ATAI Acquired, ABT Lifts Outlook, APLM On Watch
- Price Alert · Jul 16 at 10:47 AM
U.S. stock market mid-session update: Apollomics rises 12.04%, boosting confidence in meeting Nasdaq listing requirements
- rttnews · Jul 15 at 10:42 PM
Top Biotech Gainers: APLM Climbs 22%; IOVA, RCEL On Watch; MANE Gains On Hair Loss Data
